Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,497 questions · 1,590 findings · 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 281 · 17.7%GRADE not reported 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (very low certainty).

1 finding from 1 review

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Toxicity: cardiac toxicity (any grade) · treatment of relapsed epithelial ovarian cancer

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in toxicity: cardiac toxicity (any grade) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Anti‐angiogenic therapy vs no anti‐angiogenic therapy

Overall survival ( · people with HGG

Anti‐angiogenic therapy showed no clear difference in overall survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review
Show 1 more finding

Anti‐angiogenic therapy vs no anti‐angiogenic therapy

Progression‐free survival · people with HGG

Anti‐angiogenic therapy leads to lower progression‐free survival ( compared with no anti‐angiogenic therapy (high certainty).

4 findings from 1 review
Show 1 more finding